ALDH2 Suppresses Ferroptosis and Promotes Bortezomib Resistance in Multiple Myeloma Through the KEAP1‐NRF2 Feedback Loop [PDF]
Advanced Science, EarlyView.ALDH2, which is overexpressed in multiple myeloma, competitively binds KEAP1 to stabilize NRF2 by blocking its ubiquitin‐proteasomal degradation. Stabilized NRF2 translocates into the nucleus to upregulate the expression of GPX4. In parallel, NRF2 binds to the ALDH2 promoter to regulate its transcription, forming a positive feedback loop that represses
Ruonan Shao +10 more
wiley +2 more sources
Bortezomib-based chemotherapy in Chinese pediatric patients with relapsed/refractory acute lymphoblastic leukemia: A single-center retrospective study. [PDF]
Pediatr InvestigBortezomib‐based chemotherapy achieved an 88.9% remission rate in Chinese pediatric patients with relapsed/refractory B‐cell acute lymphoblastic leukemia, enabling 62.5% of responders to bridge to transplantation, while T‐cell acute lymphoblastic leukemia showed no response.
Zhao X +5 more
europepmc +4 more sources
Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations [PDF]
Biomolecules, 2021 Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug Administration. It can bind to the amino acid residues of the 26S proteasome, thereby causing the death of tumor cells. BTZ plays an irreplaceable role in the treatment of mantle cell lymphoma and multiple myeloma.
Jianhao Liu +4 more
openaire +3 more sources
Single-cell analysis reveals favorable responses of tumor-associated monocytes to bortezomib-based treatment in multiple myeloma. [PDF]
NPJ Precis OncolCheng T, Wu H, Jing R, Li Y, Wei R.
europepmc +3 more sources
Breathless on bortezomib [PDF]
BMJ Case Reports, 2011 The authors describe a case of episodic acute pneumonitis occurring after repeated doses of bortezomib, a drug being used increasingly to treat multiple myeloma. The delay in presentation each time with fever, dyspnoea, hypoxia and interstitial radiological changes contributed to under-recognition of this complication, which has so far been described ...
Devaki, O'Riordan +3 more
openaire +2 more sources
Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation. [PDF]
J Manag Care Spec PharmGautam S +7 more
europepmc +3 more sources
PLoS ONE, 2013 BACH2, a B-cell specific transcription factor, plays a critical role in oxidative stress-mediated apoptosis. Bortezomib (Velcade(TM)) is widely used to treat relapsed mantle cell lymphoma (MCL) patients despite varying clinical outcomes.
Zheng Chen +8 more
doaj +1 more source
Iron increases the susceptibility of multiple myeloma cells to bortezomib
Haematologica, 2013 Multiple myeloma is a malignant still incurable plasma cell disorder. Pharmacological treatment based on proteasome inhibition has improved patient outcome; however, bortezomib-resistance remains a major clinical problem.
Alessandro Campanella +8 more
doaj +1 more source
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
Protein & Cell, 2018 Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of
Li Yang +13 more
doaj +1 more source
Effective response with bortezomib retreatment in relapsed multiple myeloma
Swiss Medical Weekly, 2012 Previous studies have shown that retreatment of relapsed/refractory multiple myeloma (MM) with a second course of bortezomib therapy could be effective in heavily pre-treated patients.
Christian Taverna +4 more
doaj +1 more source